Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1591 AL 1605

Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer's Disease and MCI: A Review

Rao RV, Subramaniam KG, Gregory J, Bredesen AL, Coward C, Okada S, Kelly L, Bredesen DE.

Int J Mol Sci. 2023 Jan 14;24(2):1659. doi: 10.3390/ijms24021659.

Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis

Bonvicini M, Travaglini S, Lelli D, Antonelli Incalzi R, Pedone C.

Nutrients. 2023 Jan 12;15(2):386. doi: 10.3390/nu15020386.

State-of-the-art therapy for Down syndrome

Lorenzon N, Musoles-Lleó J, Turrisi F, Gomis-González M, De La Torre R, Dierssen M.

Dev Med Child Neurol. 2023 Jul;65(7):870-884. doi: 10.1111/dmcn.15517. Epub 2023 Jan 24.

Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial

Wunderlich G, Blahova Z, Garcia M, Jessen F.

Alzheimers Res Ther. 2023 Jan 28;15(1):24. doi: 10.1186/s13195-023-01163-3.

Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study

Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, Zheng H, Fisseha N, Kalluri HV, Rendenbach-Mueller B, Budur K, Gold M.

Brain. 2023 Jun 1;146(6):2275-2284. doi: 10.1093/brain/awad024.

Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer's Disease?

Mills ZB, Faull RLM, Kwakowsky A.

Int J Mol Sci. 2023 Feb 6;24(4):3205. doi: 10.3390/ijms24043205.

Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium

Shpakov AO, Zorina II, Derkach KV.

Int J Mol Sci. 2023 Feb 7;24(4):3278. doi: 10.3390/ijms24043278.

A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8-year Follow-up Study

Pakdaman H, Amini Harandi A, Gharagozli K, Siavoshi F, Shirzadeh Barough S, Sharifipour E, Esfandani A, Ilkhani S, Tabatabaei FS, Sobhanian SA.

Curr Aging Sci. 2023;16(3):234-239. doi: 10.2174/1874609816666230224111759.

Therapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation

Zhang M, Tang Z.

Biomed Pharmacother. 2023 May;161:114474. doi: 10.1016/j.biopha.2023.114474. Epub 2023 Mar 4.

Psychometric properties of the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial

Potashman M, Pang M, Tahir M, Shahraz S, Dichter S, Perneczky R, Nolte S.

BMC Geriatr. 2023 Mar 6;23(1):124. doi: 10.1186/s12877-022-03527-0.

Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment

Singh A, Ansari VA, Mahmood T, Ahsan F, Wasim R, Shariq M, Parveen S, Maheshwari S.

Drug Res (Stuttg). 2023 Jun;73(5):247-250. doi: 10.1055/a-2015-8041. Epub 2023 Mar 8.

Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies

Dong X, Zhou S, Nao J.

Ageing Res Rev. 2023 Jun;87:101910. doi: 10.1016/j.arr.2023.101910. Epub 2023 Mar 15.

Re-remembering the influence of randomized β-carotene on cognitive decline

Kopec RE, Chasman DI, Okereke OI, Sesso HD.

Alzheimers Dement. 2023 Aug;19(8):3718-3721. doi: 10.1002/alz.13018. Epub 2023 Mar 20.

New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease

Pradhan SP, Sahu PK, Behera A.

Mol Cell Biochem. 2023 Dec;478(12):2739-2762. doi: 10.1007/s11010-023-04696-1. Epub 2023 Mar 22.

Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer's disease

Fitzgerald GS, Chuchta TG, McNay EC.

CNS Neurosci Ther. 2023 Jun;29(6):1449-1469. doi: 10.1111/cns.14160. Epub 2023 Mar 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias